Loading
Designed the second-generation CAR with a CD28 costimulatory domain that made CAR-T therapy work.
Michel Sadelain's laboratory at MSKCC created the CD19-targeted second-generation chimeric antigen receptor with a CD28 signalling domain, the design underlying axicabtagene ciloleucel and brexucabtagene autoleucel, and showed that costimulation was the key to making engineered T cells persist and kill. He led the first CD19 CAR-T trials in adult ALL with Renier Brentjens and pioneered CRISPR-targeted CAR insertion into the TRAC locus. He moved to Columbia in 2024.
| Title | Journal | Year |
|---|---|---|
| The basic principles of chimeric antigen receptor design | Cancer Discovery | 2013 |
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Science Translational Medicine | 2013 |
| Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection | Nature | 2017 |
| ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma | New England Journal of Medicine | 2017 |
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma and the tags cell-therapy, car-t.
Shares Science Translational Medicine, CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma and the tags cell-therapy, car-t.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tags cell-therapy, car-t.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma and the tag cell-therapy.